International Stem Cell Stock Price, News & Analysis (OTCMKTS:ISCO)

$1.60 0.08 (5.26 %)
(As of 12/12/2017 12:56 PM ET)
Previous Close$1.52
Today's Range$1.50 - $1.60
52-Week Range$0.90 - $2.50
Volume8,166 shs
Average Volume7,266 shs
Market Capitalization$6.23 million
P/E RatioN/A
Dividend YieldN/A
Beta0.19

About International Stem Cell (OTCMKTS:ISCO)

International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company's segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company's subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson's disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products.

Receive ISCO News and Ratings via Email

Sign-up to receive the latest news and ratings for ISCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ISCO
CUSIPN/A
Phone760-940-6383

Debt

Debt-to-Equity RatioN/A
Current Ratio0.38%
Quick Ratio0.22%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.16 million
Price / Sales0.93
Cash FlowN/A
Price / CashN/A
Book Value$0.87 per share
Price / Book1.84

Profitability

Trailing EPS($0.54)
Net Income$-1,070,000.00
Net Margins-34.49%
Return on Equity-184.54%
Return on Assets-33.09%

Miscellaneous

Employees38
Outstanding Shares4,150,000

International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions

What is International Stem Cell's stock symbol?

International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO."

How were International Stem Cell's earnings last quarter?

International Stem Cell Corp (OTCMKTS:ISCO) posted its earnings results on Monday, August, 14th. The biotechnology company reported ($0.25) EPS for the quarter. The biotechnology company had revenue of $1.76 million for the quarter. International Stem Cell had a negative return on equity of 184.54% and a negative net margin of 34.49%. View International Stem Cell's Earnings History.

When will International Stem Cell make its next earnings announcement?

International Stem Cell is scheduled to release their next quarterly earnings announcement on Wednesday, April, 4th 2018. View Earnings Estimates for International Stem Cell.

Who are some of International Stem Cell's key competitors?

Who are International Stem Cell's key executives?

International Stem Cell's management team includes the folowing people:

  • Andrey Semechkin Ph.D., Co-Chairman of the Board, Chief Executive Officer
  • Donald Arthur Wright, Independent Co-Chairman of the Board
  • Jennifer Stephens, Chief Financial Officer
  • Russell Kern Ph.D., Executive Vice President, Chief Scientific Officer
  • Charles J. Casamento, Executive Director and Principal, The Sage Group
  • Paul V. Maier, Independent Director

How do I buy International Stem Cell stock?

Shares of International Stem Cell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is International Stem Cell's stock price today?

One share of International Stem Cell stock can currently be purchased for approximately $1.60.

How big of a company is International Stem Cell?

International Stem Cell has a market capitalization of $6.23 million and generates $7.16 million in revenue each year. The biotechnology company earns $-1,070,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. International Stem Cell employs 38 workers across the globe.

How can I contact International Stem Cell?

International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected]


MarketBeat Community Rating for International Stem Cell (ISCO)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

International Stem Cell (OTCMKTS:ISCO) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

International Stem Cell (OTCMKTS:ISCO) Earnings History and Estimates Chart

Earnings by Quarter for International Stem Cell (OTCMKTS:ISCO)

International Stem Cell (OTCMKTS ISCO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/4/2018        
8/14/2017Q2 2017($0.25)$1.76 millionViewN/AView Earnings Details
5/17/2017Q1 2017($0.78)$2.01 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.30)$1.94 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.01)($0.01)$1.90 million$1.96 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.01)($0.01)$1.85 million$1.59 millionViewN/AView Earnings Details
11/13/2013($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

International Stem Cell (OTCMKTS:ISCO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for International Stem Cell (OTCMKTS:ISCO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

International Stem Cell (OTCMKTS ISCO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 82.32%
Insider Trades by Quarter for International Stem Cell (OTCMKTS:ISCO)

International Stem Cell (OTCMKTS ISCO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/8/2017Wright DonDirectorSell18,639$1.50$27,958.50View SEC Filing  
12/7/2017Andrey SemechkinCEOBuy1,860,810$1.75$3,256,417.50View SEC Filing  
5/22/2017Andrey SemechkinCEOBuy3,200$1.64$5,248.00View SEC Filing  
3/22/2017Andrey SemechkinCEOBuy10,000$1.67$16,700.00View SEC Filing  
3/14/2017Andrey SemechkinCEOBuy8,100$1.41$11,421.00View SEC Filing  
12/8/2016Andrey SemechkinCEOBuy285,714$1.75$499,999.50View SEC Filing  
9/14/2016Andrey SemechkinCEOBuy200,000$1.75$350,000.00View SEC Filing  
8/22/2016Andrey SemechkinCEOBuy154,285$1.75$269,998.75View SEC Filing  
6/29/2016Andrey SemechkinCEOBuy215,000$1.75$376,250.00View SEC Filing  
8/6/2014Ruslan SemechkinMajor ShareholderBuy1,000,000$0.10$100,000.00View SEC Filing  
1/22/2013Andrey SemechkinCEOBuy10,000,000$0.20$2,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

International Stem Cell (OTCMKTS ISCO) News Headlines

Source:
DateHeadline
International Stem Cell Corp (ISCO) CEO Andrey Semechkin Bought $3.3 million of SharesInternational Stem Cell Corp (ISCO) CEO Andrey Semechkin Bought $3.3 million of Shares
finance.yahoo.com - December 9 at 11:08 AM
International Stem Cell Corp. (ISCO) Director Wright Don Sells 18,639 SharesInternational Stem Cell Corp. (ISCO) Director Wright Don Sells 18,639 Shares
www.americanbankingnews.com - December 8 at 6:22 PM
Insider Buying: International Stem Cell Corp. (ISCO) CEO Buys $3,256,417.50 in StockInsider Buying: International Stem Cell Corp. (ISCO) CEO Buys $3,256,417.50 in Stock
www.americanbankingnews.com - December 8 at 5:30 PM
International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinsons DiseaseInternational Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease
finance.yahoo.com - November 29 at 11:14 AM
International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017
finance.yahoo.com - November 18 at 2:39 AM
BRIEF-International Stem Cell Corp posts positive interim clinical results for Parkinsons disease clinical trialBRIEF-International Stem Cell Corp posts positive interim clinical results for Parkinson's disease clinical trial
www.reuters.com - November 13 at 4:20 PM
International Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinsons Disease Clinical TrialInternational Stem Cell Corporation Announces Positive Interim Clinical Results for Parkinson's Disease Clinical Trial
finance.yahoo.com - November 13 at 4:20 PM
International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinsons Disease at Neuroscience 2017International Stem Cell Corporation to Present Six-Month Results of Neural Stem Cell Transplantation for Parkinson's Disease at Neuroscience 2017
finance.yahoo.com - November 8 at 10:40 AM
International Stem Cell Corporation Receives Key Stem Cell Patent in AustraliaInternational Stem Cell Corporation Receives Key Stem Cell Patent in Australia
finance.yahoo.com - October 31 at 11:59 PM
International Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver DiseasesInternational Stem Cell Corporation Developed 3D Bioprinting Technology Targeted to Treat Liver Diseases
finance.yahoo.com - October 9 at 7:59 PM
Company Uses Patients Own Cells To Put An End To Baldness, Aging Skin And Tendon DegenerationCompany Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon Degeneration
www.forbes.com - September 29 at 10:11 PM
International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and ... - GlobeNewswire (press release)International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and ... - GlobeNewswire (press release)
globenewswire.com - September 28 at 9:12 PM
SA biotech headed west to try and score potential clients and cashSA biotech headed west to try and score potential clients and cash
www.bizjournals.com - September 27 at 4:57 PM
BRIEF-International Stem Cell to expand its revenue generating biomedical businessesBRIEF-International Stem Cell to expand its revenue generating biomedical businesses
www.reuters.com - September 26 at 5:05 PM
International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical TrialsInternational Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical Trials
finance.yahoo.com - September 26 at 10:18 AM
"Stem Cell Therapy: A Rising Tide - How Stem..."Stem Cell Therapy: A Rising Tide - How Stem...
www.benzinga.com - September 20 at 9:33 PM
Cellular Dynamics International Signs Agreement with Nanion Technologies to Enhance Mutual Offerings for ResearchersCellular Dynamics International Signs Agreement with Nanion Technologies to Enhance Mutual Offerings for Researchers
www.businesswire.com - September 20 at 9:33 PM
International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical TrialInternational Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial
finance.yahoo.com - September 20 at 4:31 PM
International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017International Stem Cell Corp. :ISCO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 7:30 PM
International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinsons DiseaseInternational Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease
finance.yahoo.com - September 7 at 8:29 PM
FDA cracks down on stem cell clinicsFDA cracks down on stem cell clinics
www.cnn.com - August 29 at 12:39 AM
International Stem Cell Corp. (ISCO) Releases Quarterly  Earnings ResultsInternational Stem Cell Corp. (ISCO) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 9:52 AM
International Stem Cell Corporation Announces Operating Results for the Three and Six-Months ended June 30, 2017International Stem Cell Corporation Announces Operating Results for the Three and Six-Months ended June 30, 2017
finance.yahoo.com - August 14 at 11:09 PM
BRIEF-International Stem Cell receives approval to start second patient cohort in clinical trial for Parkinson’s diseaseBRIEF-International Stem Cell receives approval to start second patient cohort in clinical trial for Parkinson’s disease
www.reuters.com - May 11 at 11:35 PM
Stem Cells Market 2022 Global Trends and Analysis Research Report Now Available at ReportsnReports.comStem Cells Market 2022 Global Trends and Analysis Research Report Now Available at ReportsnReports.com
www.marketwatch.com - May 11 at 11:35 PM
3 Things In Biotech You Should Learn Today: April 27, 20173 Things In Biotech You Should Learn Today: April 27, 2017
seekingalpha.com - April 28 at 6:57 PM
INTERNATIONAL STEM CELL CORP Files SEC form 10-K, Annual ReportINTERNATIONAL STEM CELL CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 6:00 PM
INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive AgreementINTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 1 at 11:39 AM
INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andINTERNATIONAL STEM CELL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
biz.yahoo.com - January 18 at 6:31 PM
BRIEF-International Stem Cell Q3 revenue falls 9 pct to $1.94 mlnBRIEF-International Stem Cell Q3 revenue falls 9 pct to $1.94 mln
www.reuters.com - November 16 at 5:57 PM
Edison Issues Update on International Stem Cell (ISCO)Edison Issues Update on International Stem Cell (ISCO)
www.prnewswire.com - August 2 at 10:30 AM
ISC-hpNSC transplantation is being evaluated for the treatment of Parkinson’s DiseaseISC-hpNSC transplantation is being evaluated for the treatment of Parkinson’s Disease
globenewswire.com - July 28 at 8:45 AM
Stem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research ConventionStem Cell Partnership: Patient Advocates And Scientists At The International Society For Stem Cell Research Convention
www.huffingtonpost.com - July 10 at 5:17 PM
INTERNATIONAL STEM CELL CORP Files SEC form 8-K, Unregistered Sale of Equity SecuritiesINTERNATIONAL STEM CELL CORP Files SEC form 8-K, Unregistered Sale of Equity Securities
biz.yahoo.com - July 6 at 2:08 PM
International Stem Cell Corp (ISCO.PK)International Stem Cell Corp (ISCO.PK)
www.reuters.com - June 17 at 5:36 PM

SEC Filings

International Stem Cell (OTCMKTS:ISCO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

International Stem Cell (OTCMKTS ISCO) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.